Table 1

Coronary artery stents as antirestenosis devices—evidence from randomised trials and improved clinical outcome with changes in antithrombotic adjunctive treatment

		STRESS			BENESTENT I			BENESTENT II			EPISTENT
		Stent (n=205)	PTCA (n=202)		Stent (n=259)	PTCA (n=257)		Stent + heparin coating (n=413)	PTCA (n=410)		Stent + abciximab (n=794)	Stent + placebo (n=809)
End points	% of patients
Early events (< 30 days)
Success	99.5	96.5^1-150		–	–		96	95		–	–
Stent thrombosis	3.5	2.7		3.4	1.5		0.2	1.7		0	0.7
Death	0	1.5		0	0		0	0.2		0.3	0.6
MI	5.4	5.0		3.5	3.1		2.7	3.2		4.4	9.4
CABG	2.4	4.0		3.1	1.5		0.7	0.5		0.8	1.2
Vascular access site complications	7.3	4.0		13.5	3.1^1-150		1.2	1.0		1.5^1-151	2.2^1-151
Hospital stay	5.8	2.8^1-150		8.5	3.1^1-150		2.8	2.3		–	–
Events up to 6 months
Death	1.5	1.5		0.4	0.8		0.2	0.5		0.5	1.2
MI	6.3	6.9		4.3	4.7		3.2	3.6		5.2	10.3^1-150
CABG	4.9	8.4		6.2	4.3		1.5	1.5		4.6	4.3
PCI	11.2	12.4		13.5	23.3^1-150		8	13.7		7.5	9.3
Restenosis	31.6	42.1^1-150		22	32^1-150		16	31^1-150		–	–
TVR	10.2	15.4		13.5	23^1-150		9.2	13.8		8.7	10.6
Events up to 1 year
Death	–	–		1.2	0.8		1.0	1.0		2.4	1.0^1-150
MI	–	–		5.4	5.1		3.4	4.4		–	–
CABG	–	–		8.1	5.8		1.9	1.5		–	–
PCI	–	–		17.8	26.8^1-150		9.4	15.6^1-150		–	–

↵1-150 p < 0.05;
↵1-151 defined as major bleeding (minor bleeding episodes were 2.9% for stent + abciximab and 1.7 for stent + placebo).